

REMARKS

The claims are 1 to 4.

The above amendment is responsive to points set forth in the Official Action.

With regard to the rejection under 35 U.S.C. 112, the claims have been amended to recite 8 wt% as the upper limit of the pyrimidine compound, per the Examiner's comments.

Further, claim 1 now recites that the pyrimidine ring is optionally substituted with amino per the Examiner's suggestion.

A Claim of Priority accompanies.

Submitted herewith is an IDS enclosing copies of the references discussed at page 2 of the Specification.

Favorable action is now requested.

Respectfully submitted,

Kiyokazu SHUKU et al.

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

By: Matthew M. Jacob
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kes
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
November 1, 2005